Learn what AI-designed small molecule drugs are and how machine learning, deep learning, and generative models are revolutionizing small molecule discovery by exploring chemical space, optimizing ADMET, and accelerating R&D timelines.
Discover how tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist, is transforming type 2 diabetes care with superior glycemic control, significant weight loss, and next-generation protein–peptide drug design.
Discover how AI and machine learning are revolutionizing pharmacovigilance—from automated case intake and triage to advanced signal detection using real-world data like EHRs, claims, social media, and wearables—to improve drug safety and protect patients in real time.
Discover how Nirmatrelvir‑X, an AI‑designed 3CL protease inhibitor, uses generative models, resistance-aware design, and multi‑objective optimization to stay ahead of SARS‑CoV‑2 variants and future coronavirus threats.
Discover how AI and machine learning are revolutionizing pharmacovigilance by enabling proactive drug safety surveillance, real-time signal detection, and smarter use of real-world data while meeting regulatory expectations and keeping patients at the center.
Learn what targeted protein degraders (TPDs) are, how PROTACs harness the ubiquitin–proteasome system to eliminate disease-causing proteins, why degradation can outperform traditional inhibition, and how these therapies are advancing into clinical trials.
Discover how AI and machine learning are revolutionizing pharmacovigilance—from automated adverse event case intake to intelligent signal detection—enabling faster, more accurate, and proactive drug safety monitoring.
Discover how deucravacitinib, a first‑in‑class oral TYK2 inhibitor, delivers biologic‑like efficacy in plaque psoriasis with once‑daily dosing, high selectivity, and a potentially improved safety profile compared with traditional JAK inhibitors.
Explore how quantum-ready small molecule oncology drugs are transforming precision cancer therapy. Learn how AI-driven de novo design, ultra-large virtual screening, and quantum-inspired simulations enable mutation-aware, network-level, and ADMET-optimized cancer drug discovery.
Discover how tirzepatide, a rationally engineered dual GIP and GLP‑1 receptor agonist, delivers superior glycemic control, profound weight loss, and improved cardiometabolic outcomes through advanced peptide design and extended half‑life.